Am J Gastroenterol . Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundi

[tetano]

Am J Gastroenterol


. 2020 Aug 27.
doi: 10.14309/ajg.0000000000000828. Online ahead of print.
Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice


Clementine Levy[SUP] 1 [/SUP], Guillaume Lassailly[SUP] 2 [/SUP], Erika Parmentier[SUP] 1 [/SUP], Thibault Duburcq[SUP] 1 [/SUP], Philippe Mathurin[SUP] 2 [/SUP], Julien Poissy[SUP] 1 [/SUP]



Affiliations

• PMID: 32858566
• DOI: 10.14309/ajg.0000000000000828

Abstract

Introduction: We investigated the potential hepatotoxicity of lopinavir/ritonavir recently used in the treatment of Severe Acute Respiratory Syndrome Coronavirus.
Methods: This is a retrospective cohort of critical patients in a teaching hospital: 12 treated with lopinavir/ritonavir and 30 in the standard-of-care group.
Results: Elevation occurred more frequently in patients treated with lopinavir/ritonavir (33% vs 6.7%).
Discussion: Caution is advised regarding the use of lopinavir/ritonavir in the most severe cases of Severe Acute Respiratory Syndrome Coronavirus.